FINWIRES · TerminalFinancial News · Live TerminalLIVE

$REGN

41 stories mentioning REGNUpdated just now

Every FINWIRES story that references REGN, newest first.

Regeneron Fails to Meet Primary Endpoint in Phase 3 Skin Cancer Trial; Shares Down Pre-Bell

Regeneron Pharmaceuticals (REGN) said late Friday that two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.The combination demonstrated a numeric 5.1-month improvement in median progression-free survival compared to pembrolizumab monotherapy, but did not reach statistical significance for the primary endpoint, Regeneron said.Regeneron said that detailed results from the trial will be presented at an upcoming medical meeting.A phase 3 head-to-head trial of the high-dose fianlimab combination compared with Opdualag is ongoing, the company added.Shares of the company were down more than 11% in Monday's premarket activity.Price: $616.00, Change: $-82.25, Percent Change: -11.78%

Regeneron's Eylea Franchise on 'Solid Footing' Despite HD Sales Miss in Q1, Oppenheimer Says

Regeneron Pharmaceuticals' (REGN) Q1 results reflected mixed trends, as weaker-than-expected sales of high-dose Eylea weighed on shares, though the broader franchise remains "on solid footing," Oppenheimer said in a note Wednesday.The biotechnology company posted non-GAAP earnings of $9.47 per diluted share, surpassing analyst expectations, but the stock faced downward pressure after Eylea HD recorded $468 million in sales, below the $490 million consensus, the brokerage said.The Eylea franchise got a boost with the US Food and Drug Administration approval of "extended dosing" intervals for HD in wet age-related macular degeneration and diabetic macular edema, according to the note. A decision on a pre-filled syringe is expected in Q2 and Oppenheimer said label expansion for HD could support adoption and help offset market share pressure.Dupixent remains a "key growth driver," supported by "durable demand" and new indications, including chronic spontaneous urticaria and allergic fungal rhinosinusitis, according to the note.Despite competition, the company's outlook is balanced, supported by Dupixent growth, expanding Eylea HD uptake, and expected higher collaboration profits with Sanofi (SNY), the brokerage said.Oppenheimer maintained an outperform rating on Regeneron, with a price target of $865.Shares of Regeneron were up more than 3% in Thursday trading.Price: $707.76, Change: $+21.40, Percent Change: +3.12%

Raymond James Adjusts Regeneron Pharmaceuticals Price Target to $902 From $910

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

Leerink Partners Adjusts Regeneron Pharmaceuticals Price Target to $792 From $873

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

Barclays Adjusts Regeneron Pharmaceuticals Price Target to $917 From $923

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $788 From $796

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $968 From $967

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $706.67, Change: $+20.31, Percent Change: +2.96%

Bernstein Adjusts Regeneron Pharmaceuticals PT to $916 From $913

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $706.12, Change: $+19.76, Percent Change: +2.88%

Cantor Fitzgerald Adjusts Regeneron Pharmaceuticals PT to $800 From $779

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $706.12, Change: $+19.76, Percent Change: +2.88%

Wells Fargo Adjusts Regeneron Pharmaceuticals PT to $800 From $825

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $706.12, Change: $+19.76, Percent Change: +2.88%

RBC Trims Price Target on Regeneron Pharmaceuticals to $762 From $779, Keeps Sector Perform Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $695.73, Change: $+9.37, Percent Change: +1.37%

Research92d ago

Research Alert: CFRA Retains Buy Rating On Shares Of Regeneron Pharmaceuticals, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $846 from $866, based on 16.1x our 2027 EPS estimate, below REGN's 10-year historical forward P/E average. We raise our 2026 EPS estimate to $47.92 from $45.59 and our 2027 EPS estimate to $52.62 from $46.25. Shares of REGN are down nearly 8% today despite the company reporting a strong start to 2026, with Q1 sales up 19% Y/Y and adjusted EPS of $3.57, beating expectations. While REGN acknowledged the temporary interruption in bulk manufacturing at its Ireland facility that negatively impacted the GAAP gross margin, we think the market reaction has been too strong as product availability was not affected and full production is expected to resume by end of Q2. We continue to think 2026 could be a pivotal year, with several key approvals and the initiation of 18 Phase 3 studies. We also positively view the April 23 agreement with the Trump administration, and REGN's commitment to Most Favored Nation pricing while receiving three years of tariff relief on pharmaceutical imports.

Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $800, Maintains Overweight Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $886.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $690.03, Change: $-41.75, Percent Change: -5.70%

Research92d ago

Research Alert: Regn Posts Strong Q1 Fueled By Dupixent And Eylea Hd Amid Manufacturing Issues

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Regeneron delivered robust Q1 2026 results with total revenues of $3.6B (+19% Y/Y) and non-GAAP EPS of $9.47 (+15% Y/Y), beating consensus estimates. The EYLEA franchise continues to transition from traditional EYLEA to EYLEA HD, with HD sales reaching $468M (+52% Y/Y) while traditional sales declined to $473M (-36% Y/Y) due to biosimilar competition. We view the underlying portfolio strength as encouraging, with Dupixent maintaining exceptional momentum at global sales of $4.9B (+33% Y/Y) and physician unit demand for EYLEA HD increasing 10% sequentially despite inventory normalization. Management expects manufacturing disruptions at the Limerick facility to normalize by the end of Q2, lowering full-year GAAP gross margin guidance to 77%-78%. We believe the company's diversified revenue base and deep pipeline of nearly 50 clinical programs, including the recent Otarmeni approval and advancing Factor XI antibody Phase 3 studies, position REGN well for continued growth despite near-term manufacturing headwinds.

Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $913 From $921, Maintains Outperform Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $886.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $738.61, Change: $-27.41, Percent Change: -3.58%

Sector Update: Health Care Stocks Edge Lower Late Afternoon

Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each easing about 0.1%.The iShares Biotechnology ETF (IBB) fell 1.8%.In sector news, Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical cannabis as a less-dangerous drug, the Associated Press reported, citing a statement from Blanche.In corporate news, Molina Healthcare (MOH) shares jumped more than 12% after the firm reported Q1 adjusted EPS that beat market expectations in the previous day.Grace Therapeutics (GRCE) tumbled 46% after the US Food and Drug Administration issued a complete response letter for its new drug application for GTx-104, an intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage.Thermo Fisher Scientific (TMO) raised its full-year outlook as Q1 results came in stronger than expected, but organic growth fell short of analysts' estimates. Its shares fell 9.5%.Regeneron Pharmaceuticals (REGN) has struck a deal with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported. Regeneron gained 2.5%.

$GRCE$MOH$REGN$TMO

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) fell 1.9%.In sector news, Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical cannabis as a less-dangerous drug, the Associated Press reported, citing a statement from Blanche.In corporate news, Thermo Fisher Scientific (TMO) raised its full-year outlook as Q1 results came in stronger than expected, but organic growth fell short of analysts' estimates. Shares fell 11%.Regeneron Pharmaceuticals (REGN) has struck an agreement with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported. Regeneron shares rose 1.6%.Novo Nordisk (NVO) said a phase 3a trial of oral semaglutide in children and adolescents aged between 10 and 17 years with type-2 diabetes showed a "superior reduction" in a measure of blood sugar control over placebo. Shares were down 2.6%.

Regeneron Says FDA Granted Accelerated Approval for Genetic Hearing Loss Therapy

Regeneron (REGN) said Thursday that the US Food and Drug Administration has granted accelerated approval for Otarmeni therapy indicated for the treatment of pediatric and adult patients with OTOF gene-related hearing loss.FDA's approval was based on the ongoing Chord trial that showed 16 of 20 participants experienced hearing improvements per pure tone audiometry assessments, while 14 out of 20 demonstrated an auditory brainstem response, according to a statement.Otarmeni's continued approval may be contingent upon verification and description of clinical benefit in the confirmatory portion of the Chord trial, Regeneron said.The company said it will provide Otarmeni at no cost to clinically eligible individuals in the US.Shares of the company were up 2% in Thursday trading.Price: $761.47, Change: $+14.89, Percent Change: +1.99%

Market Chatter: Regeneron Reaches Drug Pricing Deal, Gains US Nod for Rare Deafness Therapy

Regeneron Pharmaceuticals (REGN) has struck an agreement with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported on Thursday, citing a person familiar with the matter.Regeneron was the last company asked by Trump to align US costs with those in other developed countries under a most favored nations policy.The administration has pressured major pharmaceutical firms to sign pricing agreements to offer discounted prices or align costs with international markets, in exchange for incentives such as tariff exemptions.According to the report, the Food and Drug Administration is expected to authorize the treatment for an ultra-rare inherited hearing-loss condition caused by a genetic mutation.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $763.89, Change: $+17.31, Percent Change: +2.32%

Street Color: Regeneron Pharmaceuticals Reaches Agreement With Trump Administration to Cut Drug Prices, Bloomberg Reports

Street Color: Regeneron Pharmaceuticals Reaches Agreement With Trump Administration to Cut Drug Prices, Bloomberg Reports

Showing 21-40 of 41

Track with the FINWIRES app suite

Track REGN in your portfolio

Analyze REGN options with the wheel strategy

See market sentiment on REGN